Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial

This phase 1b trial (NCT02670044) evaluated venetoclax-idasanutlin in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) ineligible for cytotoxic chemotherapy. Two-dimensional dose escalation (DE, n = 50) was performed for venetoclax daily with idasanutlin on days 1 to 5 in 28-day cycles, followed by dosing schedule optimization (n = 6) to evaluate reduced venetoclax schedules (21-/14-day dosing). Common adverse events (occurring in ≥40% of patients) included diarrhea (87.3% of patients), nausea (74.5%), vomiting (52.7%), hypokalemia (50.9%), and febrile neutropenia (45.5%). During DE, across all doses, composite complete remission (CRc; CR + CR with incomplete blood count recovery + CR with incomplete platelet count recovery) rate was 26.0% and morphologic leukemia-free state (MLFS) rate was 12%. For anticipated recommended phase 2 doses (venetoclax 600 mg + idasanutlin 150 mg; venetoclax 600 mg + idasanutlin 200 mg), the combined CRc rate was 34.3% and the MLFS rate was 14.3%. Pretreatment IDH1/2and RUNX1mutations were associated with higher CRc rates (50.0% and 45.0%, respectively). CRc rate in patients with TP53mutations was 20.0%, with responses noted among those with co-occurring IDHand RUNX1mutations. In 12 out of 36 evaluable patients, 25 emergent TP53mutations were observed; 22 were present at baseline with low TP53variant allele frequency (median 0.0095% [range, 0.0006-0.4]). Venetoclax-idasanutlin showed manageable safety and encouraging efficacy in unfit patients with R/R AML. IDH1/2and RUNX1mutations were associated with venetoclax-idasanutlin sensitivity, even in some patients with co-occurring TP53mutations; most emergent TP53clones were preexisting. Our findings will aid ongoing/future trials of B-cell lymphoma-2/p53-murine double minute 2 inhibitor combinations. This trial was registered at www.clinicaltrials.govas #NCT02670044.